The study of Aescuven forte in improving lower urinary tract symptoms in benign prostatic hyperplasia patients with histological prostatitis after transurethral resection of the prostate

doi:10.3877/cma.j.issn.1674-3253.2019.04.007

Abstract

Abstract:

Objective

To evaluate the therapeutic efficacy of Aescuven forte on lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH) patients with histological prostatitis after transurethral resection of prostate (TURP).

Methods

From November 2015 to May 2018, 116 BPH patients with histological prostatitis were randomized divided into two groups with 58 cases in the treatment group and 58 cases in the control group. The treatment group received aescuven forte 2 pieces bid started at 3 days after surgery and continued till 4 weeks after catheter removal, while the control group received no such treatment. The IPSS and QOL scores were observed before surgery and at 7 days, 28 days after catheter removal. The numbers of AUR and UUI after surgery were counted.

Results

The IPSS and QOL scores after surgery were significantly lower than the those before surgery in both groups. But there were significant difference in the declining range between the two groups (P<0.05). The incidence of UUI was much lower in the treatment group than that in the control group (P<0.05), while the incidence of AUR in two groups showed no statistical difference (P>0.05).

Conclusion

Aescuven forte can improve the LUTS after TURP in BPH patients with histological prostatitis.

Key words: Prostatic hyperplasia, Resection of prostate, Prostatitis, Aescuven forte, Lower urinary tract symptoms

Wei Qu, Chunhui Yan, Feng Liu, Jianxin Ying, Ting Liu, Xining Ji. The study of Aescuven forte in improving lower urinary tract symptoms in benign prostatic hyperplasia patients with histological prostatitis after transurethral resection of the prostate[J]. Chinese Journal of Endourology(Electronic Edition), 2019, 13(04): 242-245.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2019.04.007

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2019/V13/I04/242

Figures/Tables 1

References 16

[1]	Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic[J]. BJU Int, 2013, 112(4):432-441.
[2]	黄向华，覃斌，梁毅文，等. 合并组织学前列腺炎的良性前列腺增重患者TURP手术对下尿路症状的影响[J]. 中华男科学杂志, 2013, 19(1): 35-39.
[3]	Qian X, Kong X, Qian Y, et al. Therapeutic efficacy of Cernilton in benign prostatic hyperplasia patients with histological prostatitis after transurethral resection of the prostate[J]. Int J Clin Exp Med, 2015, 8(7): 11268-11275.
[4]	张峰，阿斯木江·阿不拉，张立东. 组织学前列腺炎对良性前列腺增生、前列腺癌患者临床特点的影响[J]. 中华男科学杂志, 2014, 20(4): 354-358.
[5]	Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH)[J]. BJU Int, 2013, 112(4): 432-41.
[6]	阮黎，华兴，李刚，等. 组织学前列腺炎对经尿道前列腺剜除术的影响和临床意义[J/CD]. 中华腔镜泌尿外科杂志（电子版）, 2014, 8(2): 81-84.
[7]	虞永江，夏佳，钱苏波，等. 慢性前列腺炎患者前列腺电切术后下尿路症状及膀胱颈挛缩发生的临床研究[J]. 中国男科学杂志, 2017, 31(5): 12-14,19.
[8]	Doluoglu OG, Gokkaya CS, Aktas BK, et al. Impact of asymptomatic prostatitis on re-operations due to urethral stricture or bladder neck contracture developed after TURP[J]. Int Urol Nephrol, 2012, 44(4): 1085-1090.
[9]	李锋. 选择性α1受体阻滞剂在经尿道前列腺汽化电切术后早期的应用价值[J]. 中华老年医学杂志, 2013, 32(2): 178-179.
[10]	Wang H, Zhang L, Jiang N A, et al. Anti-inflammatory effects of escin are correlated with the glucocorticoid receptor/NF-κB signaling pathway, but not the COX/PGF2α signaling pathway[J]. Exp Ther Med, 2013, 6(2): 419-422.
[11]	Ficarra V, Rossanese M, Zazzara M, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy[J]. Curr Urol Rep, 2014, 15(12): 463.
[12]	Qian X, Kong X, Qian Y, et al. Therapeutic efficacy of Cernilton in benign prostatic hyperplasia patients with histological prostatitis after transurethral resection of the prostate[J]. Int J Clin Exp Med, 2015, 8(7): 11268-112675.
[13]	Domanski D, Zegrocka-Stendel O, Perzanowska A, et al. Molecular Mechanism for Cellular Response to β-Escin and Its Therapeutic Implications[J]. PLoS One, 2016, 11(10): e0164365.
[14]	Zhang F, Man X, Yu H, et al. Synergistic protective effects of escin and low dose glucocorticoids against vascular endothelial growth factor induced blood retinal barrier breakdown in retinal pigment epithelial and umbilical vein endothelial cells[J]. Mol Med Rep，2015, 11(2): 1372-1377.
[15]	Wada N, Watanabe M, Kita M, et al. Analysis of bladder vascular resistance before and after prostatic surgery in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction[J]. Neurourol Urodyn, 2012, 31(5): 659-663.
[16]	Li M, Lu C, Zhang L, et al. Oral administration of escin inhibits acute inflammation and reduces intestinal mucosal injury in animal models[J]. Evid Based Complement Alternat Med, 2015(2): 503617.

组别	IPSS（分，±s）			QOL（分，±s）			AUR[例（%）]		UUI[例（%）]
组别	术前	拔管后7d	拔管后28d	术前	拔管后7 d	拔管后28 d	拔管后7 d内	拔管后28 d内	拔管后7 d内	拔管后28 d内
治疗组	28.4±3.3	8.8±2.9^*	5.93±2.14^*	5.2±0.7	1.7±0.7^*	0.8±0.6^*	1（1.7）	1（1.7）	3（5.2）^*	2（3.4）
对照组	28.1±3.0	11.1±2.5^*	7.3±1.6^*	5.1±0.6	2.0±0.6^*	1.1±0.6^*	1（1.7）	2（3.4）	10（17.2）	3（5.2）
P值	0.704	0.0002	0.002	0.827	0.018	0.041	0.999		<0.001

组别	IPSS（分，±s）			QOL（分，±s）			AUR[例（%）]		UUI[例（%）]
组别	术前	拔管后7d	拔管后28d	术前	拔管后7 d	拔管后28 d	拔管后7 d内	拔管后28 d内	拔管后7 d内	拔管后28 d内
治疗组	28.4±3.3	8.8±2.9^*	5.93±2.14^*	5.2±0.7	1.7±0.7^*	0.8±0.6^*	1（1.7）	1（1.7）	3（5.2）^*	2（3.4）
对照组	28.1±3.0	11.1±2.5^*	7.3±1.6^*	5.1±0.6	2.0±0.6^*	1.1±0.6^*	1（1.7）	2（3.4）	10（17.2）	3（5.2）
P值	0.704	0.0002	0.002	0.827	0.018	0.041	0.999		<0.001

Please choose a citation manager

Content to export